SpringWorks Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good afternoon, everyone. We are excited to welcome the team from SpringWorks here for the 42nd Annual Goldman Healthcare Conference.
Maybe just to kick it off, I'm going to turn it over to Saqib to give us an overview of SpringWorks and what they're up to these days?
Great. Thank you so much, Corinne, and thank you to the team at Goldman for having us once again at the conference. If we can just turn to, I think we have 1 slide here that we're going to go through that essentially lays out the 3 different segments in oncology, in which we are active. We've got 12 different clinical programs ongoing in these 3 areas. And the span is relatively broad, and we've got data that's emergent in each of these areas over the course of 2021.
First, in late-stage trial in oncology, where we've got our DeFi study, Phase III top line data expected in the back half of this year. We have our MEK inhibitor that we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
